Prognostic factors in patients with advanced prostate cancer

Mark S. Soloway, Satoru Ishikawa, Roger Van Der Zwaag, Barbara Todd

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

One hundred ten patients with metastatic prostate cancer (Stage D2) were analyzed to determine the associations among time until progression and the pretreatment testosterone level, extent of bone metastases as indicated by a semiquantitative grading scale for extent of disease, performance status, race, age, and the pretreatment level of prostatic acid phosphatase (PAP). The median follow-up period was twenty-one months, with a range of four to eighty-nine months. All patients received androgen deprivation at the time metastases were identified. A multivariate analysis demonstrated that pretreatment serum testosterone was the most significant variable associated with time until progression (P < 0.01) and that the extent of bone metastases observed on the bone scan was the second most important variable (P < 0.05). The following factors did not significantly correlate with progression free intervals: age, race, and PAP. The performance status was significantly correlated, but was nonsignificant in the multivariate analysis when the model already included the testosterone level and the extent of bone metastases. Patients with a pretreatment testosterone level of less than 300 ng/dL and with more than six areas of increased uptake on the bone scan progressed more rapidly.

Original languageEnglish
Pages (from-to)53-56
Number of pages4
JournalUrology
Volume33
Issue number5 SUPPL.
DOIs
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Testosterone
Bone and Bones
Neoplasm Metastasis
Multivariate Analysis
Androgens
Serum
prostatic acid phosphatase

ASJC Scopus subject areas

  • Urology

Cite this

Soloway, M. S., Ishikawa, S., Van Der Zwaag, R., & Todd, B. (1989). Prognostic factors in patients with advanced prostate cancer. Urology, 33(5 SUPPL.), 53-56. https://doi.org/10.1016/0090-4295(89)90107-6

Prognostic factors in patients with advanced prostate cancer. / Soloway, Mark S.; Ishikawa, Satoru; Van Der Zwaag, Roger; Todd, Barbara.

In: Urology, Vol. 33, No. 5 SUPPL., 01.01.1989, p. 53-56.

Research output: Contribution to journalArticle

Soloway, MS, Ishikawa, S, Van Der Zwaag, R & Todd, B 1989, 'Prognostic factors in patients with advanced prostate cancer', Urology, vol. 33, no. 5 SUPPL., pp. 53-56. https://doi.org/10.1016/0090-4295(89)90107-6
Soloway MS, Ishikawa S, Van Der Zwaag R, Todd B. Prognostic factors in patients with advanced prostate cancer. Urology. 1989 Jan 1;33(5 SUPPL.):53-56. https://doi.org/10.1016/0090-4295(89)90107-6
Soloway, Mark S. ; Ishikawa, Satoru ; Van Der Zwaag, Roger ; Todd, Barbara. / Prognostic factors in patients with advanced prostate cancer. In: Urology. 1989 ; Vol. 33, No. 5 SUPPL. pp. 53-56.
@article{ef7bc6a3da5d41f496a55c3d0003ce5b,
title = "Prognostic factors in patients with advanced prostate cancer",
abstract = "One hundred ten patients with metastatic prostate cancer (Stage D2) were analyzed to determine the associations among time until progression and the pretreatment testosterone level, extent of bone metastases as indicated by a semiquantitative grading scale for extent of disease, performance status, race, age, and the pretreatment level of prostatic acid phosphatase (PAP). The median follow-up period was twenty-one months, with a range of four to eighty-nine months. All patients received androgen deprivation at the time metastases were identified. A multivariate analysis demonstrated that pretreatment serum testosterone was the most significant variable associated with time until progression (P < 0.01) and that the extent of bone metastases observed on the bone scan was the second most important variable (P < 0.05). The following factors did not significantly correlate with progression free intervals: age, race, and PAP. The performance status was significantly correlated, but was nonsignificant in the multivariate analysis when the model already included the testosterone level and the extent of bone metastases. Patients with a pretreatment testosterone level of less than 300 ng/dL and with more than six areas of increased uptake on the bone scan progressed more rapidly.",
author = "Soloway, {Mark S.} and Satoru Ishikawa and {Van Der Zwaag}, Roger and Barbara Todd",
year = "1989",
month = "1",
day = "1",
doi = "10.1016/0090-4295(89)90107-6",
language = "English",
volume = "33",
pages = "53--56",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5 SUPPL.",

}

TY - JOUR

T1 - Prognostic factors in patients with advanced prostate cancer

AU - Soloway, Mark S.

AU - Ishikawa, Satoru

AU - Van Der Zwaag, Roger

AU - Todd, Barbara

PY - 1989/1/1

Y1 - 1989/1/1

N2 - One hundred ten patients with metastatic prostate cancer (Stage D2) were analyzed to determine the associations among time until progression and the pretreatment testosterone level, extent of bone metastases as indicated by a semiquantitative grading scale for extent of disease, performance status, race, age, and the pretreatment level of prostatic acid phosphatase (PAP). The median follow-up period was twenty-one months, with a range of four to eighty-nine months. All patients received androgen deprivation at the time metastases were identified. A multivariate analysis demonstrated that pretreatment serum testosterone was the most significant variable associated with time until progression (P < 0.01) and that the extent of bone metastases observed on the bone scan was the second most important variable (P < 0.05). The following factors did not significantly correlate with progression free intervals: age, race, and PAP. The performance status was significantly correlated, but was nonsignificant in the multivariate analysis when the model already included the testosterone level and the extent of bone metastases. Patients with a pretreatment testosterone level of less than 300 ng/dL and with more than six areas of increased uptake on the bone scan progressed more rapidly.

AB - One hundred ten patients with metastatic prostate cancer (Stage D2) were analyzed to determine the associations among time until progression and the pretreatment testosterone level, extent of bone metastases as indicated by a semiquantitative grading scale for extent of disease, performance status, race, age, and the pretreatment level of prostatic acid phosphatase (PAP). The median follow-up period was twenty-one months, with a range of four to eighty-nine months. All patients received androgen deprivation at the time metastases were identified. A multivariate analysis demonstrated that pretreatment serum testosterone was the most significant variable associated with time until progression (P < 0.01) and that the extent of bone metastases observed on the bone scan was the second most important variable (P < 0.05). The following factors did not significantly correlate with progression free intervals: age, race, and PAP. The performance status was significantly correlated, but was nonsignificant in the multivariate analysis when the model already included the testosterone level and the extent of bone metastases. Patients with a pretreatment testosterone level of less than 300 ng/dL and with more than six areas of increased uptake on the bone scan progressed more rapidly.

UR - http://www.scopus.com/inward/record.url?scp=0024555268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024555268&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(89)90107-6

DO - 10.1016/0090-4295(89)90107-6

M3 - Article

C2 - 2775378

AN - SCOPUS:0024555268

VL - 33

SP - 53

EP - 56

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5 SUPPL.

ER -